Merck 2Q Revenues: $11.8 billion (+12%) 2Q Earnings: $2.7 billion (+56%) YTD Revenues: $22.6 billion (+10%) YTD Earnings: $5.5 billion (earnings were $2.5 billion YTD18) Comments: KEYTRUDA sales were up 58% in the quarter to $2.6 billion. Human Health Vaccines sales were up 33% to $2.0 billion. JANUVIA / JANUMET sales were down 6% to $1.4 billion. GARDASIL / GARDASIL 9 sales were up 46% to $886 million. PROQUAD, M-M-R II and VARIVAX sales were up 58% to $675 million. BRIDION sales were up ...